logo
logo

PharmaLegacy Laboratories completes acquisition of BTS Research to strengthen preclinical services and expand operations

Sep 16, 2024•about 1 year ago

Acquiring Company

PharmaLegacy Laboratories

Acquired Company

BTS Research

ShanghaiSan DiegoHealth CareBiotechnology

Description

PharmaLegacy Laboratories, a provider of in vitro and in vivo preclinical drug development services, has strategically acquired BTS Research, a San Diego-based CRO. This acquisition strengthens and expands PharmaLegacy’s global research capabilities and service offerings, allowing them to better serve clients across North America and advance their position as an industry-leading preclinical CRO.

Company Information

Company

PharmaLegacy Laboratories

Location

Shanghai, Shanghai, China

About

PharmaLegacy Laboratories is a reputable provider of in vitro and in vivo preclinical drug development services, offering a wide range of preclinical pharmacology and research services to life science organizations. With a focus on efficiency and cost-effectiveness, PharmaLegacy has a proven track record of contributing to over 400 IND applications and providing validated in vitro and in vivo services across a variety of diseases.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed